PT2237783E - Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib - Google Patents

Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib Download PDF

Info

Publication number
PT2237783E
PT2237783E PT97042568T PT09704256T PT2237783E PT 2237783 E PT2237783 E PT 2237783E PT 97042568 T PT97042568 T PT 97042568T PT 09704256 T PT09704256 T PT 09704256T PT 2237783 E PT2237783 E PT 2237783E
Authority
PT
Portugal
Prior art keywords
imatinib
pharmaceutically acceptable
acceptable salt
treatment
cmin
Prior art date
Application number
PT97042568T
Other languages
English (en)
Portuguese (pt)
Inventor
Yanfeng Wang
Elisabeth Wehrle
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40435094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2237783(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2237783E publication Critical patent/PT2237783E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT97042568T 2008-01-23 2009-01-21 Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib PT2237783E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2294508P 2008-01-23 2008-01-23

Publications (1)

Publication Number Publication Date
PT2237783E true PT2237783E (pt) 2014-12-23

Family

ID=40435094

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97042568T PT2237783E (pt) 2008-01-23 2009-01-21 Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib

Country Status (14)

Country Link
US (3) US20100298338A1 (https=)
EP (1) EP2237783B1 (https=)
JP (2) JP5936821B2 (https=)
KR (1) KR101579993B1 (https=)
CN (1) CN101951910B (https=)
AU (1) AU2009206566A1 (https=)
BR (1) BRPI0906504A2 (https=)
CA (1) CA2712087A1 (https=)
ES (1) ES2526537T3 (https=)
MX (1) MX2010008103A (https=)
PL (1) PL2237783T3 (https=)
PT (1) PT2237783E (https=)
RU (1) RU2537223C2 (https=)
WO (1) WO2009094360A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753391C1 (ru) * 2020-09-29 2021-08-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ оптимизации лечения стромальных опухолей желудочно-кишечного тракта

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0127922D0 (en) * 2001-11-21 2002-01-16 Novartis Ag Organic compounds
CN101693031A (zh) * 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
US7329495B2 (en) * 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
PT2068938E (pt) * 2006-09-22 2011-03-23 Novartis Ag Optimização do tratamento da leucemia filadélfia positiva com o inibidor de tirosina quinase abl imatinib
PE20081157A1 (es) 2006-11-07 2008-09-26 Novartis Ag Forma cristalina de hemifumarato de alisquireno

Also Published As

Publication number Publication date
EP2237783A1 (en) 2010-10-13
WO2009094360A1 (en) 2009-07-30
CA2712087A1 (en) 2009-07-30
JP5936821B2 (ja) 2016-06-22
JP2014094946A (ja) 2014-05-22
US20170035757A1 (en) 2017-02-09
JP2011510086A (ja) 2011-03-31
BRPI0906504A2 (pt) 2015-07-14
JP5881671B2 (ja) 2016-03-09
US20160045501A1 (en) 2016-02-18
US9763944B2 (en) 2017-09-19
CN101951910A (zh) 2011-01-19
RU2537223C2 (ru) 2014-12-27
PL2237783T3 (pl) 2015-04-30
ES2526537T3 (es) 2015-01-13
CN101951910B (zh) 2013-07-17
AU2009206566A1 (en) 2009-07-30
KR101579993B1 (ko) 2015-12-23
US20100298338A1 (en) 2010-11-25
MX2010008103A (es) 2010-08-23
RU2010134916A (ru) 2012-02-27
EP2237783B1 (en) 2014-11-19
KR20100105778A (ko) 2010-09-29

Similar Documents

Publication Publication Date Title
ES3060133T3 (en) Composition and method of treating cancer associated with egfr mutation
DK2558095T3 (en) ORGANIC RELATIONSHIP FOR USE IN TREATMENT OF DELIVERY CANCER
Holdhoff et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor
AU2016244279B2 (en) Method of adjuvant cancer treatment
BR112015023483B1 (pt) Uso de um inibidor de b-raf e um inibidor de mek ½”
WO2020079993A1 (ja) 抗精神病薬及びその用途
TW201127383A (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
ES2738864T3 (es) Combinaciones de inhibidores de MEK, EGFR y ERBB2 en el tratamiento del cáncer de pulmón causado por un mutante de KRAS
PT2237783E (pt) Método para optimização do tratamento de doenças proliferativas mediadas pela kit receptor com actividade tirosinacinase com imatinib
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
JP4522261B2 (ja) ブドウ膜黒色腫の処置
RU2774612C2 (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
KR20240164549A (ko) 암 치료를 위한 metap2 억제제를 포함하는 조합
CN117858725A (zh) Erk1/2和egfr抑制剂组合疗法
CN117897158A (zh) Erk1/2和shp2抑制剂组合疗法
US20060167006A1 (en) Method of treatment
US20060106026A1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer
US20030191131A1 (en) Use of organic compounds
BR112019005046B1 (pt) Combinação farmacêutica, seu uso, composição farmacêutica, usos de um inibidor de craf e de um inibidor de erk, e kit